Introduction
Peripheral T cell lymphomas (PTCLs) are a group of aggressive lymphomas derived from mature T cells or NK cells and have a dismal prognosis (1-4). Current treatments for PTCLs are ineffective, with high relapse rates that are largely due to the lack of targeted therapeutics and a thorough mechanistic understanding of the molecular pathogenesis (1, 3, 5) . Recent exome sequencing has unveiled the coexistence of recurrent somatic mutations in the small GTPase RhoA and the 5-methylcytosine (5mC) oxidase TET2 in PTCLs, but not in other types of hematological malignancies (6) (7) (8) . Most notably, mutations in both TET2 and RhoA are frequently observed (~60%-70%) in angioimmunoblastic T cell lymphoma (AITL) (6) (7) (8) , one of the most common subtypes of PTCLs, with a median overall survival of 18 months (9) . Patients with AITL often have autoimmune manifestations (e.g., hemolytic anemia, rheumatoid arthritis, or autoimmune thyroiditis) (1, 2, 10, 11), but the mechanistic underpinnings remain poorly understood.
TET2 belongs to the ten-eleven translocation (TET) family of 2-oxoglutarate-dependent (2OG-dependent) dioxygenases, a class of DNA-modifying enzymes that successively oxidize 5mC to 5-hydroxymethylcytosine (5hmC, the major catalytic product), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) in the mammalian genome (12) (13) (14) (15) (16) . These oxidative products can be ultimately excised and replaced by unmodified cytosine to achieve active DNA demethylation. Although TET2 loss-offunction mutations are observed in a large fraction of patients with lymphoid or myeloid malignancies (16) (17) (18) (19) (20) (21) (22) , they are also present in healthy elderly individuals with clonal hematopoiesis (23) . Genetic depletion of TET2 in mice causes increased selfrenewal of hematopoietic stem and progenitor cells (HSPCs) and biased HSPC differentiation toward the myeloid lineage, but it seldom leads to overt development of hematological malignancies (20, (24) (25) (26) . Together, these findings suggest that TET2 inactivation contributes to the initiation of lymphoma or leukemia (27) , but that additional mutations are required for full-blown malignant transformation.
Ras homolog family member A (RhoA) is a small GTPase that cycles between an active GTP-bound state and an inactive GDPbound state, the balance of which is controlled by the coordinated actions of GAPs and GEFs (28) . Inhibition of Rho signaling in thymus by overexpressing the bacterial toxin C3 transferase resulted in aggressive thymic lymphoma of T cell origin (29) , indicating that RhoA-mediated signaling is critical for the maintenance of T cell function (30) . Recent exome sequencing has unveiled a spectrum of RhoA mutations in patients with leukemia or lymphoma (1, 3, 5, 31) , with both loss-and gain-of-function mutations implicated in the development of malignant T cell phenotypes (31) . Among those mutations, RhoA G17V , together with TET2 loss-of-function mutaAngioimmunoblastic T cell lymphoma (AITL) represents a distinct, aggressive form of peripheral T cell lymphoma with a dismal prognosis. Recent exome sequencing in patients with AITL has revealed the frequent coexistence of somatic mutations in the Rho GTPase RhoA (RhoA
G17V
) and loss-of-function mutations in the 5-methylcytosine oxidase TET2. Here, we have demonstrated that TET2 loss and RhoA G17V expression in mature murine T cells cooperatively cause abnormal CD4 + T cell proliferation and differentiation by perturbing FoxO1 gene expression, phosphorylation, and subcellular localization, an abnormality that is also detected in human primary AITL tumor samples. Reexpression of FoxO1 attenuated aberrant immune responses induced in mouse models adoptively transferred with T cells and bearing genetic lesions in both TET2 and RhoA. Our findings suggest a mutational cooperativity between epigenetic factors and GTPases in adult CD4 + T cells that may account for immunoinflammatory responses associated with AITL patients.
Mutations in 5-methylcytosine oxidase TET2 and RhoA cooperatively disrupt T cell homeostasis
Results

TET2 loss, together with RhoA G17V expression, induces abnormal immune responses in vivo.
To determine the functional consequences of TET2 loss and RhoA G17V expression in mature T cells (particularly CD4 + and CD8 + T cells), we performed competitive adoptive T cell transfer experiments using both WT and Tet2-KO (Tet2 -/-) mice ( Figure 1A ). We isolated T cells from spleens and lymph nodes from WT and Tet2 -/-mice (Thy1.2 + ) (25) and then tions, is most frequently detected in AITL, indicating a mutational cooperativity that might contribute to the disruption of proper CD4 + T cell function in this aggressive subtype of lymphoma. Here, we investigated the loss of TET2 together with an AITL-associated RhoA mutation (RhoA G17V ) in mature T cells and mechanistically dissected how they cooperatively impinge on transcriptional and posttranslational outputs to induce aberrant immunoinflammatory responses that exacerbate disease progression. + T cells at a 1:1 ratio and injected them into TCRα-deficient recipient mice that lack the majority of endogenous TCRα + T cells ( Figure 1A ). Flow cytometric analysis showed a retroviral transduction efficiency of 45% to 70% in all the experimental groups, as indicated by GFP signals ( Supplemental Figure 1A ; supplemental material available online with this article; https://doi.org/10.1172/JCI92026DS1). The deletion of Tet2 and heterologous expression of FLAG-RhoA G17V were further confirmed by Western blotting (Supplemental Figure 1B) .
We first compared the survival of recipient mice in 4 experimental groups ( Figure 1B ). Mice transferred with WT, RhoA G17V , or
Tet2
-/-T cells remained viable, with no gross abnormalities during the 300-day experimental window. After a follow-up period of approximately 1 year, no obvious phenotypes were observed in those 3 groups of mice. In striking contrast, the survival of mice transferred with T cells harboring both genetic lesions (Tet2
) was significantly reduced, with a median survival of 21.3 weeks (red curve, Figure 1B ). Moribund mice transferred with Tet2 -/-RhoA G17V T cells displayed substantial weight loss ( Figure  1C ), severe skin ulcers on the tail, paws, and ears, accompanied by pruritus (Supplemental Figure 1C) and lymphomegaly ( Figure  1D ), as is typically seen in patients with AITL. Histopathological analysis of major organs derived from the Tet2 -/-RhoA G17V group indicated severe infiltration of both T and B lymphocytes (as indicated by anti-CD3 and anti-B220 staining, respectively) in heart, lung, and skin, but these pathological changes remained very mild or absent in the other 3 groups (Figure 1, E and F) . A thorough scrutiny of lymph nodes and spleens isolated from the Tet2 -/-RhoA G17V recipient mice further revealed a marked increase in the numbers of follicles and activated germinal centers (marked by anti-CD35 staining; Supplemental Figure 1D ). Furthermore, we observed the most notable increase in the population of germinal center B cells (B220 Figure 1E ) and elevated expression of proinflammatory IL-6 (Supplemental Figure 1F) in the Tet2 -/-RhoA G17V group, thereby recapitulating immune-related phenotypes that are commonly observed in PTCL patients (11, 32 , which agrees with the accelerated proliferation phenotype described above (Figure 2 ). These cell-cycle alterations were associated with the downregulation of p21 and upregulation of cyclin + T cells, we detected an IFN-γ increase of only approximately 1.25-fold in the double-mutation group (Supplemental Figure 3B) . Similarly, we did not observe a significant difference in the serum levels of IFN-γ between the WT and double-mutant recipient mice (Supplemental Figure 3C) ) rescued the decline of Th17 cells in the recipient mice (middle panel, red bar, Figure 3C ), a trend that was further validated in vitro by directing naive CD4 + T cell differentiation toward the Th17 lineage (Supplemental Figure 3D ). This phenotypic change agreed with the alterations in the expression of RAR-related orphan receptor γ (Rorc), which encodes RORγt, as a key transcriptional factor to mediate Th17 lineage specification (36) . Compared with WT, Rorc expression dropped by 80% in Tet2 -/-T cells, but was restored to a level comparable to WT levels in Tet2 -/-RhoA G17V CD4 + T cells (Supplemental Figure 3E) . Thus, RhoA G17V seemed to antagonize the Th17-suppressive effect associated with TET2 loss.
In parallel, we detected an approximately 80% reduction of Foxp3 + Tregs in recipient mice transferred with Tet2 -/-RhoA G17V T cells ( Figure 3C ). Foxp3 is the lineage-determining transcription factor required for the maintenance of Tregs (37) . Tregs are well known for their immunosuppressive role: they downregulate effector T cell function, maintain tolerance to self-antigens, and prevent autoimmune disease (37) . TET2 depletion in mice has been previously shown to reduce Foxp3 gene expression, with a subsequent decrease in Tregs (38) (39) (40) . Our in vitro-directed T cell differentiation study further confirmed this (Supplemental Figure 3F) . Notably, the additional introduction of RhoA G17V in Tet2 -/-T cells led to a further reduction in the expression of Foxp3 + as well as TGF-β, a key growth factor that initiates and regulates Foxp3 expression (41) (Supplemental Figure 3G ). Conversely, we observed a significant increase (~1.7-fold) in the population of CXCR5 + cells that were isolated from recipient mice using RNAsequencing (RNA-seq) (Supplemental Figure 4 , A-C). We obtained 42-96 million RNA-seq reads uniquely mapped to the transcriptome for a sample from each of the 4 groups with 2 replicates (Supplemental Figure 4A ). Replicates had Pearson correlations close to 1.00 (Supplemental Figure 4B) , indicating good reproducibility. The high quality of RNA-seq data is also indicated by the fact that all samples had good read coverage in the gene body (Supplemental Figure 4C ). Principle component analysis (PCA) and cluster analysis of gene expression data sets showed that the Tet2 -/-RhoA G17V group was most closely related to the Tet2 -/-group, but was substantially distinct from either the WT or RhoA G17V group ( Figure  4 , A-C, and Supplemental Table 1 ), indicating that TET2 loss is the major determinant responsible for changes in gene expression in Tet2 -/-RhoA G17V CD4 + T cells. Since the DNA methylation status is intimately involved in transcriptional regulation, we next measured the global 5mC and 5hmC levels in the 4 groups using a well-established dot blot assay. As expected, we found a reduction of 5hmC levels in both Tet2
-/-and Tet2 -/-RhoA G17V cells, but not in WT or RhoA G17V cells (Supplemental Figure 4D) . The global 5mC Figure 5C ) between the 2 conditions. These findings strongly imply that FoxO1 might constitute one of the key targets subjected to modulation by TET2-and RhoA-associated pathways in CD4 + T cells. Figure 6 ). We found that the loss of TET2 alone resulted in a decrease of approximately 20% in the expression of FoxO1 at a transcriptional level ( Figure 6A) , with a subsequent reduction in total protein levels of FoxO1, but not a reduction in phosphorylated FoxO1 (p-FoxO1) levels ( Figure 6B ). The RhoA G17V T cells did not show significant changes in FoxO1 gene expression, but had increased p-FoxO1, as revealed by both Western blotting ( Figure  6B ) and immunostaining ( Figure 6C ). The combined effects of TET2 loss and RhoA G17V expression, as anticipated, were a significant reduction in both the mRNA and protein levels of FoxO1, with an accompanying upregulation of its phosphorylation (Figure 6, A-C) . Previous studies have shown that p-FoxO1 is transported from the nucleus to the cytoplasm and then becomes a target for proteasomal degradation to be fully inactivated (47) . These results led us to hypothesize that FoxO1 is subjected to dual modulation by TET2-mediated DNA demethylation and RhoA-associated signaling pathways. Specifically, TET2 might regulate the transcription of FoxO1 through demethylation of the regulatory genomic regions (promoter and/or enhancer) of FoxO1, while RhoA is involved in regulating the phosphorylation and subsequent subcellular localization of FoxO1.
To test this hypothesis, we first determined the DNA methylation status at the promoter of FoxO1 using locusspecific bisulfite sequencing in the 4 experimental groups (WT, RhoA G17V ,
-/-, and Tet2 -/-RhoA G17V ). The PCA and cluster analysis showed close DNA methylation patterns between Tet2 -/-and Tet2 -/-RhoA G17V CD4 + T cells, suggesting that TET2 is the major epigenetic regulator affecting DNA methylation at FoxO1 promoters ( Figure 6D ). Among a total of 122 CpG sites within a CpG island of the FoxO1 promoter analyzed in our assay, we detected increased DNA methylation (>1.5-fold) in 26, 37, and 68 CpG sites in RhoA
G17V
,
Tet2
-/-, and Tet2 -/-RhoA G17V CD4 + T cells, respectively, when compared with WT ( Supplemental Figure 5A) . The majority of CpG sites showed a moderate increase (between 1.5-and 5-fold) in DNA methylation upon Tet2 deletion and/or RhoA G17V expression, which might be associated with the 20% decrease in FoxO1 gene expression in Tet2 -/-and Tet2 -/-RhoA G17V CD4 + T cells ( Figure 6A ). Next, to identify potential upstream factors that might control FoxO1 phosphorylation, we focused on Akt and MST1, two protein kinases that are most prominently known to regulate this process (48) . We performed Western blotting to determine the total prolevels in all the groups remained unaltered (Supplemental Figure  4E) . Given these findings, we conclude that the decrease in global 5hmC resulting from TET2 depletion might be one of the causes for transcriptional alterations in the Tet2 -/-RhoA G17V group. By comparing the differentially expressed genes (DEGs) among the 4 groups (relative to WT), we found that the Tet2 -/-RhoA G17V group displayed the most pronounced changes in gene expression, with 555 and 748 genes specifically up-or downregulated, respectively ( Figure 4C and (Figure 4 , D and E). Our unbiased comparative analysis revealed a total of 434 overlapping DEGs between the mouse and human RNA-seq data sets ( Figure 4D and Supplemental Table  1 ), which covered 22% and 11.5% of total DEGs identified in the human and mouse data sets, respectively. We further classified the overlapping DEGs according to gene clusters identified from previous human AITL RNA-seq analyses (8) Figure 4E and Supplemental Table 1 ). The majority of these overlapping genes (>73%) displayed the same trend in expression (up-or downregulation) in both the human and mouse data sets (heatmap shown in Figure 4E ; genes listed in Supplemental Table 1 ). Collectively, the mouse Tet2 -/-RhoA G17V CD4 + T cells used in our study at least partially recapitulated the gene expression signatures of human AITL tumor cells.
Gene set enrichment analysis (GSEA) of the WT and Tet2 -/-RhoA G17V groups revealed that upregulated genes were enriched in genes implicated in the cell cycle and DNA replication (e.g., cyclin family genes and cyclin-dependent kinase inhibitors; Figure 5 , A and B), a finding that resonates with the phenotypic changes in cell proliferation (Figure 2 and Supplemental Figure  2 ) and the cell cycle ( Figure 3 and Supplemental Figure 3A) . On the other end of the DEG spectrum, downregulated genes were most abundantly found under the categories of immune system and TCR signaling pathways ( Figure 5, A and B Figure 5B ).
When comparing the gene expression profiles between WT and
Tet2
-/-RhoA G17V CD4 + T cells, we further noticed that a substantial fraction of downregulated genes ( Figure 5B ) was associated with FoxO1, a forkhead family of transcriptional factors involved in reg- Supplemental Table 2 ). Notably, 17 of 43 patients displayed high mutation frequencies within the TET2 catalytic domain (TET2CD) (Supplemental Figure 5C and Supplemental Table 2 ), with 15 of 17 also having the RhoA G17V mutation (Supplemental Figure 5D ). We next asked whether there is a correlation between FoxO1 immunostaining and the mutation status in 43 AITL patients. Overall, AITL tumor cells from most patients (20 of 22) bearing both TET2 and RhoA G17V mutations showed low nuclear and/or cytosolic FoxO1 staining ( Figure 6F , Supplemental Figure 5B , and Supplemental Table 2 ). Nonetheless, AITL patients with TET2 mutations alone showed heterogeneous FoxO1 staining patterns (with 16 patients showing strong FoxO1 staining and 5 patients showing relatively weak FoxO1 staining) ( Figure 6F , Supplemental Figure 5B , and Supplemental Table 2 ), possibly due to the different TET2 mutation frequencies and the existence of additional unidentified mutations and pathways in regulating the function of FoxO1 in those AITL patients. Among all the AITL samples, not a single AITL patient was found to have RhoA G17V alone, which was consistent with previous exome sequencing results that suggest the exclusive coexistence of TET2 and RhoA mutations in patients with AITL (6) .
In aggregate, our data indicate that TET2 loss and RhoA 
Discussion
The recent exosome sequencing and integrative genomic studies of lymphoma samples have led to the discovery of recurrent mutations in epigenetic regulators (e.g., TET2, DNA methyltransferase tein and phosphorylation levels of Akt and MST1. MST1 and p-Akt have been reported to mediate FoxO1 phosphorylation and its subsequent nucleus-to-cytosol translocation (48) . As shown in Figure  6E , compared with the WT and Tet2 -/-groups, RhoA G17V and Tet2 -/-RhoA G17V cells showed higher levels of p-Akt, whereas the total Akt protein levels remained largely unaltered. Of note is that the elevated phosphorylation of FoxO1 correlated with its more abundant accumulation in the cytosol in RhoA G17V and Tet2 -/-RhoA G17V CD4 + T cells ( Figure 6C ). With regard to MST1, we observed no difference in the total or phosphorylated protein levels among the 4 groups, thus ruling out its participation in upregulating p-FoxO1. These results suggest that RhoA G17V is at least one of the causes that alters the activity of Akt and subsequently upregulates FoxO1 phosphorylation, a finding that is consistent with an earlier study performed in Jurkat T cells (8) .
To explore whether altered FoxO1 subcellular localization and/ or expression can be used as clinically relevant immunophenotypic and molecular features in human primary AITL tumor samples, we performed immunohistochemical analysis of FoxO1 in AITL tumor specimens (a total of 43 cases), as well as in lymph nodes from healthy donors. In normal lymph nodes, the IHC immunostaining of FoxO1 was detected almost exclusively in the nuclei, with strong signals (left, Figure 6F ). The FoxO1 staining patterns in the majority of AITL tumor specimens fell into 1 of the following 4 categories ( Figure 6F , Supplemental Figure 5B , and Supplemental Table 2 ): (a) negative or low staining in both the cytosol and nuclei (e.g., cases 8, 30, and 42); (b) variegated staining in both the cytosol and nuclei (e.g., cases 5, 16, and 19); (c) dominant staining in the cytosol (e.g., cases 4 and 6); or (d) dominant staining in the nuclei (e.g., cases 9, 10, and 23). To further analyze the TET2 and RhoA mutation status in these patients, we performed targeted amplicon sequencing. Among the 43 patients with AITL, 22 patients (~51%) had the RhoA G17V mutation (cooccurrence with TET2 mutations) (Supplemental Table 2 ), and all patients had TET2 mutations, but with varying mutation frequencies across the TET2 coding regions (Supplemental Figure 5C tion both in vitro and in vivo through inactivation of FoxO1. Our study showcases a previously unappreciated cooperation between an epigenetic regulator and the RhoA GTPase signaling pathway to maintain normal CD4 + T cell activity (Figure 8 ). TET2 is an epigenetic regulator and dioxygenase that catalyzes DNA methylation oxidation to mediate DNA demethylation (12) . TET2 mutations are reported in a wide spectrum of hematological disorders and neoplasms, including myelodysplastic syndromes, acute myeloid leukemia and chronic myelomonocytic leukemia, and both B and T cell lymphomas (17) (18) (19) (20) (21) (22) . Genetic disruption of TET2 in mice has been shown to promote HSPC self-renewal and biased differentiation toward the myeloid lineage (20, (24) (25) (26) . However, TET2 loss of function in general is insufficient to cause a malignant transformation of blood cells (23) , indicating that secondary mutation(s) might be needed to promote the progression of hematological malignancies (49) (50) (51) . Indeed, with respect to mature T cell function, genetic lesions in both TET2 and RhoA, but not TET2 loss or the G17V RhoA G17V mutation alone, lead to the most pronounced perturbations of the proliferation of CD4 + T 3 α [DNMT3A], and isocitrate dehydrogenase [NADP(+)] 2, mitochondrial [IDH2]) and RhoA in PTCLs (6) (7) (8) . In particular, the coexistence of somatic mutations in TET2 and RhoA is present in over 60% of patients with AITL and constitutes an aggressive subtype of PTCL that is often associated with autoimmune-like manifestations (1, 2, 10, 11). This breakthrough heralds the advent of a molecular era in the mechanistic dissection of AITL and other types of PTCL that share similar genetic defects. Here, we show that genetic depletion of TET2, together with RhoA G17V expression, results in mature CD4 + T cell abnormalities characterized by increased cell proliferation, decreased apoptosis or cell death, aberrant activation of TCR signaling, and an imbalance among Th17 cells, Tregs, and Tfh cells. The disruption of T cell homeostasis might account for the immunoinflammatory-like phenotypes observed in adoptive T cell transfer mouse models, which resemble the inflammatory background in patients with AITL (2, 11) .
In the present study, we have collected compelling evidence to support the notion that mutational cooperativity between TET2 and RhoA is required to disrupt normal CD4 + T cell func- RhoA GTPase signaling is required to balance the phosphorylation (P) state of Akt so as to control the phosphorylation of its downstream effector, FoxO1, which is indispensable for T cell proliferation and survival. Both pathways cooperatively work together to regulate the FoxO1-medaited signaling. Genetic defects in TET2 or RhoA alone may not exert an overtly detrimental effect on FoxO1. However, in patients with AITL or other types of PTCLs, TET2 loss of function and expression of the RhoA mutant (G17V) synergistically disrupt the transcriptional and posttranslational modification networks of CD4 + T cells, as most notably exemplified by combined FoxO1 inactivation through hypermethylation at its promoter region and elevated phosphorylation to drive the cytosolic translocation of nuclear FoxO1 to expedite its degradation. The inactivation of FoxO1 results in abnormal CD4 + T cell proliferation and survival and imbalanced T cell homeostasis to elicit an aberrant immune response and to further drive AITL disease progression.
is certainly associated with the transcriptional regulation of FoxO1 in CD4 + T cells, but the causal effect remains to be established. On the other hand, the inactivating mutation in RhoA GTPase (G17V) ultimately causes elevated phosphorylation of FoxO1 to promote its nucleus-to-cytosol translocation for proteasomal degradation. A genetic defect in TET2 or RhoA alone is insufficient to cause abnormal phenotypes, but the combined effects can have an overtly detrimental effect on CD4 + T cells. Loss of FoxO1 has been known to reduce the expression of apoptotic genes and Fas, which agrees with the apoptosis-suppressive phenotype we observed in Tet2 -/-RhoA G17V CD4 + T cells ( Figure 3A) . Furthermore, FoxO1 positively controls Foxp3 gene expression and maintains the proper functioning of Tregs to suppress autoimmunity (48, 53) . It has been shown that FoxO1 is a negative regulator of Th17 by inhibiting RORγt activity (54) and that inactivation of FoxO1 is essential for Tfh cell differentiation (55) . Therefore, FoxO1 inactivation arising from genetic defects in both TET2 and RhoA could lead to an imbalance in effector T cells to induce inflammatory-like phenotypes such as those we observed in recipient mice after adoptive T cell transfer. Although FoxO1 itself remains an intractable transcriptional factor to be targeted, other key regulatory factors within the FoxO1-mediated transcriptional network might provide alternative candidate pools for developing improved antilymphoma therapy. Overall, the inactivation of FoxO1 that resulted from TET2 loss and RhoA G17V provides an additional basis for devising new diagnoses, prognoses, and therapeutics for lymphoma.
In both our in vitro and in vivo studies, we did not observe malignant transformation of mature CD4 + T cells. Nonetheless, the gene expression profiles of murine Tet2 -/-RhoA G17V CD4 + T cells characterized in the current study are reminiscent of those of human AITL tumor cells. By comparing the transcriptomes of mouse CD4 + T cells harboring an AITL-like genetic background with those of human AITL tumor cells, we observed similar transcriptional output patterns (e.g., AITL signature genes [ref. 43] and critical genes involved in the immune response and cell cycle) in both cell types, thus attesting to the disease relevance of our experimental system. The overexpression of RhoA G17V on the Tet2 -/-background led to acute inflammation-like phenotypes in the mice, causing relatively early death of the animals (median survival of 21.3 weeks). This might have prevented us from observing any overt malignant transformation or tumor formation during the course of the in vivo studies. Nonetheless, our in vivo model based on adoptive T cell transfer at least partially recapitulates the immune-related clinical manifestations commonly seen in AITL patients, and thus our study is one of the few to establish a clinically relevant in vivo model for the mechanistic study of AITLassociated symptoms. In the near future, it is imperative to generate inducible, genetically modified RhoA G17V -knockin plus Tet2 -/-mice that might attenuate acute inflammation and provide a prolonged time window for potential malignant transformation, thereby enabling the generation of an improved mouse model that faithfully mimics human PTCLs.
Methods
Mouse T cell isolation. T cells were isolated using a Dynabeads Untouched Mouse T Cell Kit (Thermo Fisher Scientific). Mouse CD4 + or CD8 + T cells were purified using a mouse CD4 + or CD8 + T Cell Isolation Kit cells, including the CD4 + CD44 + T cell subsets that are regarded as cells of origin of some types of PTCLs, and may contribute to tumor cell growth and inflammatory responses (52) . In parallel, we also observed an overt Th17/Treg/Tfh functional imbalance in the double-mutation group, which might account for the inflammatory phenotype seen in recipient mice transferred with Tet2 -/-RhoA G17V T cells. Mechanistically, TET2 is involved in remodeling the transcriptional network in CD4 + T cells through its epigenetic regulatory function, whereas RhoA is more devoted to controlling TCR-associated signaling pathways in CD4 + T cells. This functional synergy is best illustrated in the dual regulation of FoxO1, as illustrated in Figure 8 . FoxO1 is one of the key transcriptional factors that maintain T cell proliferation and survival (53) . TET2 loss leads to alterations in the methylation status of the FoxO1 promoter (hypermethylation) to negatively regulate the transcription of FoxO1 (by ~20%). Although we cannot rule out the possibility that TET2 might also control DNA demethylation at distal regulatory regions (e.g., enhancer) of FoxO1, the alteration of DNA methylation at the promoter due to TET2 loss jci.org Volume 127 Number 8 August 2017
Patients' samples and custom amplicon sequencing. AITL patients' samples were collected from patients with AITL at the MD Anderson Cancer Center (USA), Fujian Medical University (China), and Zhejiang Cancer Hospital (China). Genomic DNA was isolated from AITL patients' tumor samples using a RecoverAll Total Nucleic Acid Isolation Kit for FFPE (Thermo Fisher Scientific). Targeted amplicon sequencing libraries were prepared using a TruSeq Custom Amplicon Kit (Illumina) and sequenced with the NextSeq 500 (Illumina). The mutation status of TET2 and RhoA was analyzed with an issac variation caller (https://github.com/sequencing/isaac_variant_caller) and the VarScan v2.2.3 pileup2snp function. For each sample, the Burrows-Wheeler Aligner (BWA) version 0.7.12 was used to map all sequencing reads to hg19. Picard was used to sort the align file. The issac variation caller configured with exome/target sequencing parameters call single nucleotide variants (SNVs) for each site (depth ≥20). SNV annotations were done using snpEFF software.
Accession numbers. The RNA-seq data sets are deposited in the NCBI's Gene Expression Omnibus database (GEO GSE90976).
Statistics. A minimum of 3 biological replicates were analyzed for all quantitative analysis. A 2-tailed Student's t test was used to determine statistical significance between 2 groups. For multiple group comparisons, ANOVA with Dunnett's or Tukey's post-hoc correction was used. A P value of less than 0.05 was considered statistically significant. Error bars represent the SD.
Study approval. Experiments and handling of mice were conducted following federal, state, and local guidelines under an IACUC protocol and with approval of the IACUC of the Institute of Biosciences and Technology at Texas A&M University. All patients provided informed consent under a research protocol approved by the IRBs of the MD Anderson Cancer Center, Zhejiang Cancer Hospital, and Fujian Medical University. These IRB-approved protocols were carried out in accordance with the Declaration of Helsinki principles.
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Adoptive T cell transfer. Isolated total T cells (Thy1.1 + or Thy1.2 + ) and CD4 + or CD8 + T cells were mixed together at the desired ratio in 200 μl PBS and retro-orbitally injected into 6-to 8-week-old male and female TCRα-deficient mice (purchased from The Jackson Laboratory, 1 million cells/mouse). The reconstitution efficiency of T cells was assessed by examining the GFP or mCherry fluorescence signals in peripheral blood from the recipient mice 4 weeks after adoptive cell transfer. RNA-seq library preparation and bioinformatic analysis. Poly A-tailed mRNA was enriched using a Poly(A)Purist Kit (Thermo Fisher Scientific) and followed by RNA-seq library preparation using an Ultra Directional RNA Library Prep Kit for Illumina (New England BioLabs) according to the manufacturer's instructions. RNA-seq was performed using the Illumina HiSeq 2500 or NextSeq 500 with the 75-bp pair-ended running mode. The pair-ended reads were mapped against mm10 using STAR with default parameters, and the RefSeq gene annotation was obtained from the UCSC's genome database (September 7, 2015) . The number of reads mapped to each gene was counted using HTSeq (-m intersection-nonempty, -s no, -t exon, -i gene_id; http://www.huber.embl.de/users/anders/HTSeq/), with uniquely mapped reads as input. The raw read counts across all genes were used for calculating reads per kb per million (RPKM) values. To identify the differentially expressed genes among the experimental groups, we performed negative binomial tests for pairwise comparisons between WT and RhoA 
, or Tet2
-/-RhoA G17V by using the Bioconductor package DESeq2, with a corrected P value of 0.05 or less and fold-change thresholds of greater than 2 or less than 0.5. The functional enrichment analyses of significantly differentially expressed genes between 2 conditions were performed using GSEA with a preranked function. The Pearson correlations between biological replicates were 0.99 and 1.0, indicating high reproducibility of sequencing experiments, whereas the Pearson correlations between conditions ranged from 0.96 to 0.98. For the heatmaps, row-wise scaled RPKM values across all samples were plotted using the function heatmap.2 in the R package gplots (www.r-project.org). Locus-specific DNA methylation analysis. Purified genomic DNA was subjected to bisulfite conversion using the MethylCode Bisulfite Conversion Kit (Thermo Fisher Scientific) according to the manufacturer's instructions. The primers targeted to the bisulfite-converted FoxO1 locus were designed using MethPrimer (http://www.urogene.org/ methprimer/) with default settings. The targeted amplicons were amplified using a PyroMark PCR Kit (QIAGEN), followed by library construction using a Nextera XT DNA Library Prep Kit (Illumina). The libraries were sequenced with a NextSeq 500 (Illumina) using a 75-bp pair-ended sequencing mode. The amplicon sequences were mapped to the FoxO1 promoter locus using BSMAP on the default setting (https://sites.google. com/a/brown.edu/bioinformatics-in-biomed/bsmap-for-methylation). Methylation ratios were calculated using model-based analysis of bisulfite sequencing data (MOABS) (56) .
